PNQ 201

Drug Profile

PNQ 201

Alternative Names: Ado A-2B antagonist; PNQ-201

Latest Information Update: 02 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advinus Therapeutics
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Adenosine A2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Inflammatory bowel diseases

Highest Development Phases

  • Preclinical Inflammatory bowel diseases

Most Recent Events

  • 20 Jan 2016 PNQ 201 is available for licensing as of 20 Jan 2016. http://www.advinus.com/partnering.asp
  • 20 Jan 2016 Preclinical trials in Inflammatory bowel disease in India (PO) before January 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top